Alpha 2.0
Login Register
» Authors » A-M C Dingemans

A-M C Dingemans

Explore the profile of A-M C Dingemans including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 581
Followers 0
Related Specialties
Oncology
Endocrinology
Radiology
Top 10 Co-Authors
E F Smit
H J M Groen
J L Derks
E J M Speel
B C M Hermans
A M W J Schols
J A Stigt
J H R J Degens
T J N Hiltermann
H van Tinteren
Published In
Lung Cancer
Ann Oncol
Eur J Cancer
ESMO Open
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?
Xander N, Leeneman B, Dingemans A, Fiets W, de Jong W, Uyl N, et al.
Eur J Cancer . 2024 Aug; 209:114262. PMID: 39111205
Background: The Dutch Committee for the Evaluation of Oncological Agents (cieBOM) assesses the clinical benefit of systemic anti-cancer treatments (SACTs). For SACTs tested in non-randomized trials (NRTs), cieBOM primarily utilizes...
2.
Disease relapse in relation to lymph node sampling in lung carcinoid patients
Moonen L, Derks J, Hillen L, van Suylen R, den Bakker M, von der Thusen J, et al.
Endocr Relat Cancer . 2024 Jun; 31(9). PMID: 38855984
The predictive value of the extent of peri-operative lymph node (LN) sampling in relation to disease relapse in patients with pulmonary carcinoid (PC) is unknown. Furthermore, post-surgery follow-up recommendations rely...
3.
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
Oosting S, van der Veldt A, Fehrmann R, Bhattacharya A, van Binnendijk R, GeurtsvanKessel C, et al.
ESMO Open . 2023 Jul; 8(4):101599. PMID: 37450950
No abstract available.
4.
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Remon J, Besse B, Aix S, Callejo A, Al-Rabi K, Bernabe R, et al.
Ann Oncol . 2023 Mar; 34(5):468-476. PMID: 36863484
Background: The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy of gefitinib and osimertinib. Methods: APPLE...
5.
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
van der Veldt A, Oosting S, Fehrmann R, GeurtsvanKessel C, van Binnendijk R, Dingemans A, et al.
ESMO Open . 2023 Feb; 8(1):100785. PMID: 36764094
No abstract available.
6.
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
Pruis M, Paats M, Geurts W, Dubbink H, Dingemans A
JCO Precis Oncol . 2022 Jan; 5:849-853. PMID: 34994615
No abstract available.
7.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dingemans A, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L, et al.
Ann Oncol . 2021 Apr; 32(7):839-853. PMID: 33864941
No abstract available.
8.
Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Willemsen A, Degens J, Baijens L, Dingemans A, Hoeben A, Hoebers F, et al.
Front Nutr . 2020 Dec; 7:600612. PMID: 33324671
Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS)....
9.
Letter to the Editor
Degens J, Dingemans A, Schols A, Willemsen A
Lung Cancer . 2020 Dec; 153:184. PMID: 33309334
No abstract available.
10.
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature
Hermans B, Derks J, Moonen L, Habraken C, der Thusen J, Hillen L, et al.
Lung Cancer . 2020 Nov; 150:152-158. PMID: 33171403
Objectives: Pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinomas (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic...